SpringerLink
Log in

Asprosin is a Reliable Predictor of Osteoporosis in Type 2 Diabetic Postmenopausal Women: A Case–Control Study

  • ORIGINAL RESEARCH ARTICLE
  • Published:
Indian Journal of Clinical Biochemistry Aims and scope Submit manuscript

Abstract

The study evaluates Asprosin's value in diabetic postmenopausal women, examining its reliability as a predictor for osteoporosis (OP) in the second type of diabetes (T2D) women. A case–control study recruited 255 postmenopausal women attending the geriatric department of the University Hospital. They were grouped into controls (non-OP non-T2D), and study cases. The latter were subdivided into: non-OP T2D, and OP T2D postmenopausal women (85/255) for each. Serum Asprosin level showed a significant increase in postmenopausal T2D women with OP (42.51 ± 2.97 ng/mL, P < 0.001) compared with postmenopausal T2D women without OP and controls. Additionally, there is a significant interrelationship between OP radiological indicators and bone-forming hormone in T2D women, osteocalcin. Moreover, bone resorption and glycemic markers in T2D women correlated significantly and positively with Asprosin. The Receiver operator characteristic curve discriminates OP T2D postmenopausal women from non-OP T2D postmenopausal women by estimating cutoff value (> 39.3 ng/mL) at 90% sensitivity, 63.3% specificity, and P < 0.001.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

OP:

Osteoporosis

DXA:

Dual-energy x-ray absorptiometry

BMD:

Bone mineral density

WAT:

White adipose tissue

IR:

Insulin resistance

T2D:

Type 2 diabetes

AGEs:

The advanced glycation end products

BMI:

Body mass index

HbA1c:

Glycated hemoglobin

OC:

Serum (Osteocalcin)

PTH:

Parathyroid hormone

CTX:

Serum human C-terminal telopeptides of types I collagen

MDA:

Serum malondialdehyde

SOD:

Superoxide dismutase

ALP:

Serum bone alkaline phosphatase

HOMA-IR:

Hemostatic model assessment-insulin resistance

ROC:

The receiver operator characteristic curve

References

  1. Bover J, Bailone L, López-Báez V, Benito S, Ciceri P, Galassi A, et al. Osteoporosis, bone mineral density and CKD–MBD: treatment considerations. J Nephrol. 2017;30:677–87.

    Article  PubMed  Google Scholar 

  2. Marinho BCG, Guerra LP, Drummond JB, Silva BC, Soares MMS. The burden of osteoporosis in Brazil. Arquivos Brasileiros de Endocrinol Metabol. 2014;58:434–43.

    Article  Google Scholar 

  3. Merle B, Haesebaert J, Bedouet A, Barraud L, Flori M, Schott A-M, et al. Osteoporosis prevention: Where are the barriers to improvement in French general practitioners? A qualitative study. PLoS ONE. 2019;14(7): e0219681.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Mariani G, Kasznia-Brown J, Paez D, Mikhail MN, Salama DH, Bhatla N, et al. Improving women’s health in low-income and middle-income countries. Part I: challenges and priorities. Nucl Med Commun. 2017;38(12):1019.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Hassan WN, Shallal F, Roomi AB. Prediction of successful Induction of labor using ultrasonic fetal parameters. Current Women’s Health Rev. 2022;18(1):134–9.

    Article  Google Scholar 

  6. Radecka A, Lubkowska A. The significance of dual-energy x-ray absorptiometry (DXA) examination in cushing’s syndrome—A systematic review. Diagnostics. 2023;13(9):1576.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Kuo T-R, Chen C-H. Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives. Biomarker Res. 2017;5(1):1–9.

    Article  Google Scholar 

  8. Marini S, Barone G, Masini A, Dallolio L, Bragonzoni L, Longobucco Y, et al. The effect of physical activity on bone biomarkers in people with osteoporosis: a systematic review. Front Endocrinol. 2020;11: 585689.

    Article  Google Scholar 

  9. Farrag M, Ait Eldjoudi D, González-Rodríguez M, Cordero-Barreal A, Ruiz-Fernández C, Capuozzo M, et al. Asprosin in health and disease, a new glucose sensor with central and peripheral metabolic effects. Front Endocrinol. 2023;13:1101091.

    Article  Google Scholar 

  10. Hekim MG, Kelestemur MM, Bulmus FG, Bilgin B, Bulut F, Gokdere E, et al. Asprosin, a novel glucogenic adipokine: a potential therapeutic implication in diabetes mellitus. Arch Physiol Biochem. 2021;129:1–7.

    Google Scholar 

  11. Cavati G, Pirrotta F, Merlotti D, Ceccarelli E, Calabrese M, Gennari L, et al. Role of advanced glycation end-products and oxidative stress in type-2-diabetes-induced bone fragility and implications on fracture risk stratification. Antioxidants. 2023;12(4):928.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Zhang L, Chen C, Zhou N, Fu Y, Cheng X. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clin Chim Acta. 2019;489:183–8.

    Article  CAS  PubMed  Google Scholar 

  13. Roomi AB, Nori W, Al-Badry SH. The value of serum adiponectin in osteoporotic women: does weight have an effect? J Obesity. 2021;2021.

  14. Al-Jawadi WA, Jankeer MH. Study of the balance system between some enzymatic and non-enzymatic antioxidants in blood serum of patients with rheumatoid arthritis in Mosul City, Iraq. Medico-Legal Update. 2021;21(1).

  15. Fox C, Bernardino L, Cochran J, Essig M, Bridges KG. Inappropriate use of homeostasis model assessment cutoff values for diagnosing insulin resistance in pediatric studies. J Am Osteopath Assoc. 2017;117(11):689–96.

    PubMed  PubMed Central  Google Scholar 

  16. Czerwiński E, Badurski JE, Marcinowska-Suchowierska E, Osieleniec J. Current understanding of osteoporosis according to the position of the World Health Organization (WHO) and International Osteoporosis Foundation. Ortop Traumatol Rehabil. 2007;9(4):337–56.

    PubMed  Google Scholar 

  17. Chow S-C, Shao J, Wang H, Lokhnygina Y. Sample size calculations in clinical research: CRC press; 2017.

  18. Clemente-Suárez VJ, Redondo-Flórez L, Beltrán-Velasco AI, Martín-Rodríguez A, Martínez-Guardado I, Navarro-Jiménez E, et al. The role of adipokines in health and disease. Biomedicines. 2023;11(5):1290.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Morcos YA, Lütke S, Tenbieg A, Hanisch F-G, Pryymachuk G, Piekarek N, et al. Sensitive asprosin detection in clinical samples reveals serum/saliva correlation and indicates cartilage as source for serum asprosin. Sci Rep. 2022;12(1):1340.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Naiemian S, Naeemipour M, Zarei M, Lari Najafi M, Gohari A, Behroozikhah MR, et al. Serum concentration of asprosin in new-onset type 2 diabetes. Diabetol Metab Syndr. 2020;12:1–8.

    Article  Google Scholar 

  21. Groener JB, Valkanou A, Kender Z, Pfeiffenberger J, Kihm L, Fleming T, et al. Asprosin response in hypoglycemia is not related to hypoglycemia unawareness but rather to insulin resistance in type 1 diabetes. PLoS ONE. 2019;14(9): e0222771.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Li X, Liao M, Shen R, Zhang L, Hu H, Wu J, et al. Plasma asprosin levels are associated with glucose metabolism, lipid, and sex hormone profiles in females with metabolic-related diseases. Mediat Inflammat. 2018;2018.

  23. Wang C-Y, Lin T-A, Liu K-H, Liao C-H, Liu Y-Y, Wu VC-C, et al. Serum asprosin levels and bariatric surgery outcomes in obese adults. Int J Obes. 2019;43(5):1019–25.

  24. Wang Y, Qu H, **ong X, Qiu Y, Liao Y, Chen Y, et al. Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion. Mediat Inflamm. 2018;2018.

  25. Cantay H, Binnetoglu K, Gul HF, Bingol SA. Investigation of serum and adipose tissue levels of asprosin in patients with severe obesity undergoing sleeve gastrectomy. Obesity. 2022;30(8):1639–46.

    Article  CAS  PubMed  Google Scholar 

  26. Gozel N, Kilinc F. Investigation of plasma asprosin and saliva levels in newly diagnosed type 2 diabetes mellitus patients treated with metformin. Endokrynol Pol. 2021;72(1):37–43.

    Article  CAS  PubMed  Google Scholar 

  27. Kantorowicz M, Szymura J, Szygula Z, Kusmierczyk J, Maciejczyk M, Wiecek M. Nordic walking at maximal fat oxidation intensity decreases circulating asprosin and visceral obesity in women with metabolic disorders. Front Physiol. 2021;12: 726783.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Zhang Y, Huang X, Sun K, Li M, Wang X, Han T, et al. The potential role of serum IGF-1 and leptin as biomarkers: towards screening for and diagnosing postmenopausal osteoporosis. J Inflamm Res. 2022:533–43.

  29. Mohsin S, Baniyas MM, AlDarmaki RS, Tekes K, Kalász H, Adeghate EA. An update on therapies for the treatment of diabetes-induced osteoporosis. Expert Opin Biol Ther. 2019;19(9):937–48.

    Article  CAS  PubMed  Google Scholar 

  30. Yuan M, Li W, Zhu Y, Yu B, Wu J. Asprosin: a novel player in metabolic diseases. Front Endocrinol. 2020;11:64.

    Article  Google Scholar 

  31. Haie, CHEN Hongyan, CHEN Hongjiao. The correlation between serum Asprosin levels and bone mineral density, balance ability fracture incidence in postmenopausal women, Chin J Osteopros, Feb 2021, 27:2.

  32. Alobaidi MBA, Al-Samarrai RRH. Correlation between serum asprosin level and oxidative stress in Iraqi patients with type II diabetes mellitus. Sys Rev Pharm. 2020;11(12):1729–33.

    CAS  Google Scholar 

  33. Ali EA, Tahseen YH, El-Yassin HD. Thyroid Disorders and the Level of Malondialdehyde. J Fac Med Baghdad. 2009;51(1):67–70.

    Google Scholar 

  34. Bover J, Ureña-Torres P, Torregrosa J-V, Rodríguez-García M, Castro-Alonso C, Górriz JL, et al. Osteoporosis, bone mineral density and CKD–MBD complex (I): diagnostic considerations. Nefrología (English Edition). 2018;38(5):476–90.

    Article  Google Scholar 

  35. Mishra I, Duerrschmid C, Ku Z, He Y, **e W, Silva ES, et al. Asprosin-neutralizing antibodies as a treatment for metabolic syndrome. Elife. 2021;10: e63784.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Shi X, Jiang J, Hong R, Xu F, Dai S. Circulating IGFBP-3 and interleukin 6 as predictors of osteoporosis in Postmenopausal Women: a cross-sectional study. Mediat Inflamm. 2023;2023.

  37. Seyhanli ES, Koyuncu I, Yasak IH, Demir HA, Temiz E. Asprosin and oxidative stress level in COVID-19 patients. Clin Lab. 2022;68(1).

  38. Nori W, Zghair MAG. Omicron targets upper airways in pediatrics, elderly and unvaccinated population. World J Clin Cases. 2022;10(32):12062.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Ali AI, Nori W. Correlation of serum visfatin level in non-obese women with polycystic ovary syndrome and matched control. Reprod Sci. 2022;29(11):3285–93.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors wish to thank the Ministry of Higher Education and Scientific Research in Iraq.

Funding

No funding was received for conducting this study.

Author information

Authors and Affiliations

  1. Department of Chemistry, College of Science, University of Thi-Qar, Nasiriyah, 64001, Iraq

    Ali B. Roomi

  2. Chemistry and Biochemistry, Mustansiriyah University, Baghdad, 10052, Iraq

    Eham Amer Ali

  3. Obstetrics and Gynecology, Mustansiriyah University, Baghdad, 10052, Iraq

    Wassan Nori

  4. Al-Karkh University of Science, Baghdad, Iraq

    Muntadher I. Rahmah

Authors
  1. Ali B. Roomi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eham Amer Ali
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wassan Nori
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Muntadher I. Rahmah
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ali B. Roomi.

Ethics declarations

Conflict of interest

No authors have disclosed any conflicts of interest that would have been perceived as having influenced the work presented in this paper, either financially or otherwise.

Ethical Approval

The information used in this study was obtained with approval from the Iraqi Ministry of Health. Sampling was Parental permission using informed consent. Participants' personal data is encrypted to ensure anonymity.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Roomi, A.B., Ali, E.A., Nori, W. et al. Asprosin is a Reliable Predictor of Osteoporosis in Type 2 Diabetic Postmenopausal Women: A Case–Control Study. Ind J Clin Biochem (2023). https://doi.org/10.1007/s12291-023-01163-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12291-023-01163-y

Keywords

Search

Navigation